Morgan Stanley lowered the firm’s price target on enGene (ENGN) to $19 from $34 and keeps an Overweight rating on the shares after the company reported Q2 results and provided an update on the LEGEND study of detalimogene in non-muscle invasive bladder cancer. The firm has tempered peak detalimogene share within its model as it awaits further clarity on likely commercial uptake of competing programs, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN: